Mentor Capital: Risk Mitigated Call Option on Cancer Immunotherapy

Breast Cancer Ribbon

Written by Chet Billingsley, Chairman & CEO Mentor Capital, Inc. (MNTR) 30 August 2009

$28.60 Share Price (979% Gain) Projected for MNTR on New Cancer Treatment August 30, 2009

Dear Friends & Investors:

In his Seeking Alpha article today, Mike Havrilla, PhD, and co-founder of BioMed Reports, calculated a $28.60 / share valuation projection for Mentor Capital, Inc. (MNTR), a 979% gain over the last MNTR close at $2.65/sh.

Mentor Capital, Inc. (MNTR) is the public market proxy for leading edge breast cancer therapy company, Quantum Immunologics, Inc. MNTR is the largest single shareholder in Quantum and in approximately four steps (to preserve maximum ownership for Quantum founders) Mentor looks to complete a merger and name change with Quantum.

Dr. Havrilla's 979% upward projection for MNTR is similar to the 1,000% gain already realized by Dendreon (DNDN) over 45 days during March & April 2009. DNDN is a pre-revenue, $2.7 Billion market cap, immunotherapy company that holds patents centered on the PAP protein used in prostate cancer immunotherapy.

MNTR / Quantum is an immunotherapy company that holds patents centered on the OFA protein used in breast cancer immunotherapy. OFA is also found on each of 500 other cancers tested.

Recent 12% per day Increases for MNTR Suggest Quick Action

Prior to the publication of "Mentor Capital: Risk Mitigated Call Option on Cancer Immunotherapy" in Seeking Alpha, the MNTR share price had already increased 162% in the prior 7 weeks at an accelerating pace.

A key reason the MNTR share price has quickly increased is that only 700,000 shares are currently outstanding, greatly facilitating a large percentage increase in price.

Looking forward, the general progress of MNTR / Quantum can be followed on the Cancer Immunotherapy Index covering MNTR, DNDN and 8 other immunotherapy companies. The CI Index, which has been paced by MNTR increases, projects a 1,300% overall gain for the immunotherapy sector and can be viewed at http://www.MentorCapital.com.

For investors seeking first tier biotech stock analysis and coverage, including for MNTR, there is no better source than signing up to follow Mike Havrilla, PhD, in Seeking Alpha, or joining him at BioMedReports.com. I'm sure we'll see you there.

Best in Good Health,

Chet Billingsley, Chairman & CEO

Mentor Capital, Inc. (MNTR)

Forward Looking Statements, Safe Harbor and Risk Descriptions are Incorporated by Reference from the MNTR Company Web Site at http://www.mentorcapitalcom/.

Written by Chet Billingsley, Chairman & CEO Mentor Capital, Inc. (MNTR) 30 August 2009